• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 27th April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

NICE makes 'optimised' decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.

_DSC0022
Nadine Henderson
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Optimise_AdobeStock_576507456_landscape

The National Institute for Health and Care Excellence (NICE) makes recommendations for the use of medicines in the National Health Service (NHS) in England based on their clinical and cost-effectiveness through their Technology Appraisal (TA) programme. The main decision outcomes are to ‘recommend’ the medicine (in line with marketing authorisation), ‘not recommend’ the medicine, or something in between: ‘optimised’. Optimised recommendations support the use of the medicine for a smaller group of patients than originally stated by the marketing authorisation, based on the findings of the appraisal relating to clinical or cost-effectiveness in different patient sub-groups.

The option for NICE to ‘optimise’ recommendations offers a route to treatment access for sub-groups of patients in whom a medicine offers a clinically- and cost-effective alternative to current practice in cases where this was not the case for the full patient population (determined by the licensed use and the scope of NICE’s appraisal). However, the level of patient access associated with optimised recommendations is unclear.

In this blog, we update OHE research into the proportion of NICE recommendations that are “optimised” and the extent to which “optimised” decisions restrict the eligible patient population compared to the scope of the NICE appraisal for 2020 to 2022. The method to estimate the level of patient access was developed by OHE researchers (O’Neill and Devlin, 2010). It was further utilised in our 2020 report looking at NICE decisions from 2015 to 2019 (Bulut et al., 2020).

Between 2010 and 2019, 31% of NICE’s “positive” decisions (recommended or optimised) were optimised, excluding those included in the Cancer Drugs Fund. Over the last two years (Jan 2020 to Dec 2022), this figure rose to 39%.

As part of our 2020-22 update, 16 out of 78 (21%) single technology appraisals (STAs) which had “optimised” recommendations included sufficient information to allow for the estimation of patient access. For comparison, between 2015 and 2019, 40 out of 112 (36%) appraisals included sufficient information, suggesting a decrease in the reporting of relevant information (primarily resource impact templates and statements) by NICE.

Just over half (56%) of optimised decisions recommended treatment in less than half of eligible patients, and a quarter (25%) recommended use in less than a quarter of patients within NICE’s appraisal scope. Between 2010 and 2019, these figures were 65% and 35%, respectively. On average, 45% of the patient population potentially eligible for the treatment under review was recommended for treatment in NICE’s ‘optimised’ recommendation. This is a slight increase from 39% for the period between 2015 to 2019. The overall level of access for optimised decisions from 2010 to 2022 is 36%.

NICE states that 84% of their recommendations are positive. However, a significant proportion of these are optimised recommendations, and we have demonstrated that the recommended level of patient access associated with these can be low. While the justification for these restrictions may be well-founded, more granular reporting of recommendations would help paint a more accurate picture of recommended levels of patient access associated with NICE decision outcomes.

 

Citations

Bulut, M., O’Neill, P. and Cole, A. (2020) NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?. OHE Contract Research. Available from https://www.ohe.org/publications/nice-optimised-decisions-what-recommended-level-patient-access/

O’Neill P, Devlin NJ. (2010). An analysis of NICE’s ‘restricted’ (or ‘optimized’) decisions. Pharmacoeconomics 28(11):987-93. doi: 10.2165/11536970-000000000-00000. PMID: 20936882.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • ABPI

Related Insights

RWB Netherlands air balloon_landscape
  • Insight
  • May 2023

Around The World in HTAs: The Netherlands – 5 Routes for New Tech

Read more
Slovak discounting_andrik-langfield-0rTCXZM7Xfo-unsplash_landscape
  • Insight
  • May 2023

Setting the Right Discount Rate for HTA in the Slovak Republic

Read more
Italy_Balloon_AdobeStock_177931475_landscape
  • Insight
  • April 2023

Around The World in HTAs: Italy – What’s Next?

Read more
Air balloon HTA v4
  • Insight
  • March 2023

Around The World in HTAs: Spain – Are We There Yet?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!